Anti-Infectives · LP-041
Praziquantel Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-041Anti-Infectives
- Generic identity
- PraziquantelTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-041
- Generic identity
- Praziquantel
- Presentation
- Tablet
- Catalogue strength
- 600 mg
- Catalogue pack
- Blister 6 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Praziquantel.
- Dosage form: tablet.
- Catalogue strength / concentration: 600 mg.
- Catalogue pack: Blister 6 tablets.
- Catalogue category: Anti-Infectives.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Score line/divisibility, coating, taste-masking and whether crushing/chewing is permitted.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 600 mg | Tablet | — | Blister 6 tablets | Do not infer score, divisibility, coating, dose regimen or indication from the 600 mg strength and six-tablet pack. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Praziquantel is an anthelmintic used for selected fluke and tapeworm infections. Parasite identification and the location of infection determine the appropriate clinical role. It is not a universal medicine for every parasitic disease, and the possibility of neurologic or ocular involvement changes assessment. This general educational profile does not establish the approved indications or clinical suitability of a proposed Luang Pharma tablet.
Clinical context and therapeutic role
A clinician considers travel or residence history, exposure, diagnostic testing and the suspected parasite. Some infections require follow-up testing or specialist care, and public-health treatment programs follow their own current protocols. Concurrent medicines can materially change praziquantel exposure. Liver disease, pregnancy, eye symptoms and a seizure history should be reviewed. Ongoing symptoms after treatment may reflect reinfection, tissue damage or an alternative diagnosis rather than a simple need to repeat medicine.
Selected safety context
Dizziness, drowsiness, headache and abdominal discomfort can occur. Neurologic symptoms may relate to inflammatory responses in particular infections and require urgent assessment. Important interactions include rifampicin and other medicines that strongly alter metabolism. Eye involvement requires specialist review before treatment. Avoid hazardous activities if alertness is impaired. Severe allergy, seizures, fainting or marked worsening of symptoms needs prompt care. Follow the exact tablet instructions rather than assuming it is intended to be chewed.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: PraziquantelArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-041.
Professional enquiries
Request product-specific evidence for LP-041.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.